PsychU

Sorry, this content is no longer available.

Explore Other Content
Welcome to PsychU!
Improving mental health care...together
Menu

Virtual Event – Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia

Regional/Local March 30 12:00 pm to 1:00 pm EDT
  1. Home
  2. Events
  3. Virtual Event – Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia

Thank You For Attending Today’s Webinar

Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia

This is a virtual event for PsychU members in Alabama, Florida, Georgia, and Tennessee.

Trace amines and trace amine-associated receptors (TAAR) are found throughout the brain and peripheral tissues and have modulating effects on neurotransmitters including dopamine, glutamate, and serotonin. The speakers will discuss what are some of the potential effects of TAAR1 on neurotransmitter signaling related to schizophrenia and some of the preclinical data, as well as share the potential role of TAAR1 beyond schizophrenia.

Objectives:

  • Summarize the Unmet Needs of Schizophrenia as it Relates to Neural Circuitry
  • Introduction to Trace Amines (TA) and Trace Amine-Associated Receptors (TAARs) and Their Potential Relationship to Schizophrenia
  • Discuss Potential Modulating Effects of TAAR1 on Neurotransmitter Signaling Associated with Schizophrenia Pathophysiology

Featuring

Rachel-Self

Rachel Self, PhD, MS (OPDC)

Medical Science Director, Neuroscience Field Medical Affairs

More
Aneta-Fornal

Aneta Fornal, PharmD (OPDC)

Medical Science Liaison

Jason-Carter

Jason Carter, PharmD

Senior Medical Science Liaison, Neuroscience Field Medical Affairs

Speakers Rachel Self, PhD, MS; Aneta Fornal, PharmD; and Jason Carter, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Related Events

Registration

Related Resources

  • Digital Dialogue Series Part 4

    Interview April 2, 2025

    Digital Therapeutics are health software that treat or alleviate a condition by generating and delivering an intervention. This mini series aims to deepen our understanding of this innovation.

  • World Bipolar Day – Bipolar Together

    Video March 28, 2025

    Join us as both providers and patients share their thoughts and perspectives of on the significance of World Bipolar Day and the impact of living with bipolar disorder.

  • Understanding Caregivers’ Perspectives: Agitation in Alzheimer’s Dementia

    On-Demand Webinar March 27, 2025

    Join us as we explore the caregivers’ insights on the “most bothersome” symptoms and what they view as meaningful improvements or worsening in agitation.

Join today for instant access to all PsychU content, events, and more!

Membership is free!

"*" indicates required fields

Name*
Zip / Postal Code*

Choose Your Unique Login

Your username can only contain lowercase letters (a-z) and numbers. Username cannot be the same as email address.
Email*
Password*
Your password must be at least 8 characters Hint: Must use combination of lower case letters, upper case letters, numbers and special characters like !@#$.

I AGREE TO THE FOLLOWING TERMS

I agree to the following terms:*
I agree to the following terms*

Event Registration

Hidden
Hidden

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS

PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.

PSYCHU MEMBERSHIP ELIGIBILITY

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients. NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.

MEMBERSHIP & REGISTRATION

Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.

ATTENDANCE LIMITATIONS

PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.

MEAL REPORTING

The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Hidden
Hidden

Join PsychU Today to receive a wide array of tools and benefits

  • Join our multidisciplinary community that is improving mental health care… together
  • Quickly learn more about the topics you're interested in
  • Access an award-winning library of on-demand mental health resources
  • Gain key insights from industry expert & thought leaders

Stay Connected: